L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lytix Biopharma AS
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Depreciation & Amortization
kr962k
CAGR 3-Years
N/A
CAGR 5-Years
149%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Depreciation & Amortization
kr38.6m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
9%
B
Bergenbio ASA
OSE:BGBIO
Depreciation & Amortization
kr417k
CAGR 3-Years
-29%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Depreciation & Amortization
kr6m
CAGR 3-Years
-14%
CAGR 5-Years
4%
CAGR 10-Years
39%
N
Nykode Therapeutics ASA
OSE:NYKD
Depreciation & Amortization
$2.3m
CAGR 3-Years
81%
CAGR 5-Years
209%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Depreciation & Amortization
kr817k
CAGR 3-Years
-60%
CAGR 5-Years
-32%
CAGR 10-Years
15%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Depreciation & Amortization?
Depreciation & Amortization
962k NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Depreciation & Amortization amounts to 962k NOK.

What is Lytix Biopharma AS's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
149%

Over the last year, the Depreciation & Amortization growth was 5%.

Back to Top